Clinical outcome and molecular landscape of patients with ARID1A ‐loss gastric cancer
Cancer Science · 2024-03 · 115 (3) · 905-915
DOI: 10.1111/cas.16057 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 26.12.2023. Verfasst von Mengyao Sun und 11 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, …. Hauptthemen laut MEDLINE: DNA-Binding Proteins, Stomach Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Chromatin remodelers are commonly altered in human cancer. The mutation of AT‐rich interactive domain 1A ( ARID1A) in gastric cancer (GC), a component of the SWI/SNF chromatin remodeling complex, was proven associated with treatment response in our previous study. However, ARID1A loss of function was caused not only by mutations but also copy number deletions. The clinicopathologic, genomic, and immunophenotypic correlates of ARID1A loss is largely uncharacterized in GC. Here, 819 patients with clinicopathological information and sequencing data or formalin‐fixed paraffin‐embedded tissues from four cohorts, Zhongshan Hospital (ZSHS) cohort ( n = 375), The Cancer Genome Atlas (TCGA) cohort ( n = 371), Samsung Medical Center (SMC) cohort ( n = 53), and ZSHS immunotherapy cohort ( n = 20), were enrolled. ARID1A loss was defined by genome sequencing or deficient ARID1A expression by immunohistochemistry. We found that ARID1A mutation and copy number deletion were enriched in GC with microsatellite instability (MSI) and chromosomal‐instability (CIN), respectively. In the TCGA and ZSHS cohorts, only CIN GC with ARID1A loss could benefit from fluorouracil‐based adjuvant chemotherapy. In the SMC and ZSHS immunotherapy cohorts, ARID1A loss exhibited a tendency of superior responsiveness and indicated favorable overall survival after anti‐PD‐1 immunotherapy. ARID1A ‐loss tumors demonstrated elevated mutation burden, neoantigen load, and interferon gamma pathway activation. Moreover, in CIN GC, ARID1A loss was correlated with higher homologous recombination deficiency. ARID1A loss defines a distinct subtype of GC characterized by high levels of genome instability, neoantigen formation, and immune activation. These tumors show sensitivity to both chemotherapy and anti‐PD‐1 immunotherapy. This study provides valuable insights for precision treatment strategies in GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
- Department of General Surgery, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Endoscopy, Fudan University Shanghai Cancer Center, Shanghai, China.
ORCID-Profile: Ruochen Li, Jiejie Xu
Zitieren
APA
Sun, M., Gu, Y., Fang, H., Shao, F., Lin, C., Zhang, H., Li, H., He, H., Li, R., Wang, J., Liu, H., & Xu, J. (2024). Clinical outcome and molecular landscape of patients with ARID1A ‐loss gastric cancer. Cancer Science, 115(3), 905-915. https://doi.org/10.1111/cas.16057
Vancouver
Sun M, Gu Y, Fang H, Shao F, Lin C, Zhang H, et al. Clinical outcome and molecular landscape of patients with ARID1A ‐loss gastric cancer. Cancer Science. 2024;115(3):905-915. doi:10.1111/cas.16057
BibTeX
@article{Sun2024,
author = {Sun, Mengyao and Gu, Yun and Fang, Hanji and Shao, Fei and Lin, Chao and Zhang, Heng and Li, He and He, Hongyong and Li, Ruochen and Wang, Jieti and Liu, Hao and Xu, Jiejie},
title = {Clinical outcome and molecular landscape of patients with ARID1A ‐loss gastric cancer},
journal = {Cancer Science},
year = {2024},
volume = {115},
number = {3},
pages = {905--915},
doi = {10.1111/cas.16057}
}
EUVIMED